Gilead Sciences Announces Board and Executive Compensation Changes

Ticker: GILD · Form: 8-K · Filed: 2024-07-17T00:00:00.000Z

Sentiment: neutral

Topics: governance, executive-compensation, board-changes

Related Tickers: GILD

TL;DR

Gilead's board is shuffling, with exec pay plans updated. Keep an eye on who's in and out.

AI Summary

Gilead Sciences, Inc. announced on July 17, 2024, changes in its board of directors and executive compensation. The filing details the departure of certain directors and the election of new ones, alongside updates to compensatory arrangements for key officers.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy, governance, and future performance expectations.

Risk Assessment

Risk Level: low — This filing primarily concerns corporate governance and executive compensation, which typically have a low direct impact on immediate financial risk.

Key Players & Entities

FAQ

What specific items are being reported under Item 5.02 of the 8-K?

Item 5.02 of this 8-K filing reports the departure of directors or certain officers, the election of directors, and the appointment of certain officers, as well as compensatory arrangements of certain officers.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on July 17, 2024.

What is the Commission File Number for Gilead Sciences, Inc.?

The Commission File Number for Gilead Sciences, Inc. is 0-19731.

What is the IRS Employer Identification Number for Gilead Sciences, Inc.?

The IRS Employer Identification Number for Gilead Sciences, Inc. is 94-3047598.

Where are Gilead Sciences, Inc.'s principal executive offices located?

Gilead Sciences, Inc.'s principal executive offices are located at 333 Lakeside Drive, Foster City, California 94404.

From the Filing

0001104659-24-080355.txt : 20240717 0001104659-24-080355.hdr.sgml : 20240717 20240717090101 ACCESSION NUMBER: 0001104659-24-080355 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240717 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240717 DATE AS OF CHANGE: 20240717 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GILEAD SCIENCES, INC. CENTRAL INDEX KEY: 0000882095 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943047598 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19731 FILM NUMBER: 241121056 BUSINESS ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 6505743000 MAIL ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: GILEAD SCIENCES INC DATE OF NAME CHANGE: 19930328 8-K 1 tm2419649d1_8k.htm FORM 8-K false 0000882095 0000882095 2024-07-17 2024-07-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       FORM 8-K       CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): July 17, 2024       GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter)   Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission File No.) (IRS Employer Identification No.)   333 Lakeside Drive , Foster City , California (Address of principal executive offices)   94404 (Zip Code)   650 - 574-3000 (Registrant’s Telephone Number, Including Area Code)       Not Applicable (Former name or former address, if changed since last report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ¨      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12 ¨      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value, $0.001 per share   GILD   The Nasdaq Global Select Market   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨           Item  5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.   On July 17, 2024, Gilead Sciences, Inc., a Delaware corporation (the “Company&#8

View on Read The Filing